Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...
UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...
Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...
The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...
A newly launched $5 million clinical trial program allows clinical trial sponsors to start trials in as little as 45 days in the Canadian province Ontario. | A newly launched $5 million clinical trial ...
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...
Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...
Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed ...
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, ...
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis with a $214 million contract for ...
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a ...
Kodiak plans to file for FDA approval of tarcocimab, an anti-VEGF drug also called Zenkuda, in the fourth quarter. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results